How Supplied:
Solution 40 mg/0.8 mL
Indications and Usage:
Humira is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn’s disease.
Prescribing Instructions:
Prescribing Information Instructions [PDF]
Side Effects and Contraindications:
Side effects may include tuberculosis (frequently disseminated or extrapulmonary at clinical presentation), invasive fungal infections, and other opportunistic infections. Some of these infections have been fatal. The FDA concluded that tumor necrosis factor (TNF) blockers increase risk of lymphoma and other cancers associated with the use of these drugs in children and adolescents. FDA has also identified new safety information related to the occurrence of leukemia and new-onset psoriasis in patients treated with TNF blockers. Anti-tuberculosis treatment of patients with latent tuberculosis infection reduces the risk of reactivation in patients receiving treatment with Humira. However, active tuberculosis has developed in patients receiving Humira whose screening for latent tuberculosis infection was negative. Patients should be evaluated for tuberculosis risk factors and be tested for latent tuberculosis infection prior to initiating Humira and during therapy. Treatment of latent tuberculosis infection should be initiated prior to treatment with Humira. Physicians should monitor patients receiving Humira for signs and symptoms of active tuberculosis, including patients who test negative for latent tuberculosis infections.
Company:
Abbott Laboratories
800-633-9110
www.humira.com
MyList
Drugs
